Analyst Price Target is $16.89
▲ +292.76% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Prime Medicine in the last 3 months. The average price target is $16.89, with a high forecast of $26.00 and a low forecast of $9.00. The average price target represents a 292.76% upside from the last price of $4.30.
Current Consensus is
Moderate Buy
The current consensus among 10 contributing investment analysts is to moderate buy stock in Prime Medicine. This Moderate Buy consensus rating has held steady for over two years.
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.
Read More